Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank
Invivyd, Inc. (IVVD)
Company Research
Source: GlobeNewswire
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it has signed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank. The deal allows for drawdown of capital in the future if certain conditions and milestones are met. “We are pleased to have secured this term loan facility ahead of important anticipated catalysts, including gaining alignment with the FDA on the regulatory pathway of our pipeline candidate, VYD2311,” said Bill Duke, Chief Financial Officer of Invivyd. “The non-dilutive nature of this financing facility supports balance sheet optionality so the company can focus on per-share value creation.” About VYD2311 VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- A Look at Invivyd (IVVD) Valuation After Advancing VBY329 RSV Antibody Candidate into Preclinical Development [Yahoo! Finance]Yahoo! Finance
- Invivyd (NASDAQ:IVVD) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Invivyd (NASDAQ:IVVD) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.MarketBeat
- Invivyd (NASDAQ:IVVD) had its "hold" rating reaffirmed by analysts at D. Boral Capital.MarketBeat
- Invivyd to Participate at the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
IVVD
Earnings
- 11/6/25 - Miss
IVVD
Sec Filings
- 11/25/25 - Form SCHEDULE
- 11/24/25 - Form 8-K
- 11/20/25 - Form 4
- IVVD's page on the SEC website